Lipocine completes successful meeting with fda on lpcn 1154 in postpartum depression

Lipocine and fda agreed on the acceptance criteria for the pivotal study which enables advancement of lpcn 1154 for postpartum depression (ppd) company on track to initiate dosing in the pivotal study q1'24 salt lake city , oct. 26, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary platform, today announced the completion of a meeting with the fda and guidance for the appropriate acceptance criteria for the upcoming lpcn 1154 pivotal study. ppd is a major depressive disorder with onset either during pregnancy or within four weeks of delivery, with symptoms persisting up to 12 months after childbirth.
LPCN Ratings Summary
LPCN Quant Ranking